bio-clinical-databases-acmg-classification

name	bio-clinical-databases-acmg-classification
description	Applies ACMG/AMP 2015 framework with ClinGen SVI specifications, Tavtigian 2018/2020 Bayesian point system, Abou Tayoun 2018 PVS1 decision tree, Pejaver 2022 calibrated PP3/BP4 thresholds for REVEL/BayesDel/AlphaMissense, Brnich 2020 PS3/BS3 OddsPath, Walker 2023 SpliceAI splicing framework, and AMP/ASCO/CAP 2017 tumor tiers. Use when classifying germline variants P / LP / VUS / LB / B, applying VCEP-specific CSpec rules, computing Whiffin BS1, or assigning cancer Tier I-IV per Li 2017.
tool_type	python
primary_tool	requests

Version Compatibility

Reference examples tested with: requests 2.31+, pandas 2.2+, AutoPVS1 (Xiang 2020), InterVar 2.2+, GeneBe 1.0+ (Stawinski 2024 Clin Genet). ACMG/AMP Bayesian point system is Tavtigian 2018 Genet Med / 2020 Hum Mutat. Pejaver 2022 AJHG PP3/BP4 calibrated thresholds. ClinGen Splicing Subgroup 2023 (Walker AJHG). v3.2 ACMG SF list (Miller 2023). The ACMG 2.0 framework is in development as of May 2026; not yet published.

Before using code patterns, verify installed versions match. If versions differ:

• Python: pip show <package> then help(module.function) to check signatures
• CLI: <tool> --version

If code throws ImportError, AttributeError, or TypeError, introspect the installed package and adapt the example to match the actual API rather than retrying. VCEP-specific CSpec rules override default ACMG application; the authoritative directory is https://cspec.genome.network/cspec/ui/svi/all.

ACMG/AMP Variant Classification Framework

'Classify this variant per ACMG/AMP' -> Apply 28-criterion framework using Tavtigian point system; gate on ClinGen SVI specifications and VCEP-specific overrides; assign P / LP / VUS / LB / B classification with evidence trail.

• Python (automated): GeneBe API https://api.genebe.net/cloud/api-public/v1/variant
• Python (rule-based): InterVar -> python InterVar.py -i input.vcf -b hg38 --table_annovar table_annovar.pl
• Web tools: VarSome (commercial), Franklin/Genoox (commercial), ClinGen VCI (gold standard for SVI)
• Citation: Richards 2015 Genet Med 17:405 (original framework); Tavtigian 2020 Hum Mutat 41:1734 (point system)

The Tavtigian Bayesian Point System: The Engine Inside All Modern Classifiers

Richards 2015 specified 28 criteria with strength labels (Supporting / Moderate / Strong / Very Strong); combination rules produced P / LP / VUS / LB / B. Tavtigian 2018/2020 demonstrated this framework is mathematically a Bayesian classifier and proposed the naturally-scaled point system that every modern automated classifier implements:

Strength	Points	Odds of pathogenicity
Supporting	1	2.08:1
Moderate	2	4.33:1
Strong	4	18.7:1
Very Strong	8	350:1

Benign codes are negative-signed. Final classification:

Sum of points	Category
>= 10	Pathogenic
6-9	Likely Pathogenic
0-5	VUS
-1 to -6	Likely Benign
<= -7	Benign

InterVar / GeneBe / VarSome / Franklin all implement Tavtigian point summation under the hood. Combinations never appearing in the 2015 combining rules (e.g., PVS1_VeryStrong + PM2_Supporting -> LP) emerge naturally from point arithmetic.

PVS1 Decision Tree (Abou Tayoun 2018 Hum Mutat 39:1517)

PVS1 is the most consequential code: pathogenic Very Strong (8 points) for predicted loss-of-function in a gene where LoF is established disease mechanism. The 2018 decision tree refined PVS1 from a binary into a graded code based on:

1. Variant type: nonsense / frameshift / canonical +-1,2 splice / initiation codon / single-exon deletion / multi-exon deletion.
2. NMD prediction: variant in 5'-most exon OR >50bp upstream of last exon-exon junction -> NMD-triggered. Else truncated protein.
3. Critical region: removal of >10% of coding sequence OR removal of a critical functional domain.
4. Alternative isoform: does the variant affect a transcript expressed in disease-relevant tissue?

Output strengths:

Output	Original Strength
PVS1_VeryStrong	Strongest (Very Strong)
PVS1_Strong	Strong
PVS1_Moderate	Moderate
PVS1_Supporting	Supporting

Subsumption rule (Abou Tayoun 2018): PVS1 + PP3 -> only PVS1 counts (PP3 is subsumed). Same for PVS1 + PM4.

>15 VCEP-specific PVS1 trees exist as of 2024 (CDH1, ENIGMA BRCA1/2, FH LDLR/APOB/PCSK9, InSiGHT MMR, RASopathies, hearing loss, hypertrophic cardiomyopathy, Rett/Angelman, etc.). The automated implementation is AutoPVS1 (Xiang 2020).

Pejaver 2022 PP3/BP4 Calibrated Thresholds (the load-bearing 2024+ calibration)

Pejaver 2022 AJHG 109:2163 Bayesian-calibrated 13 missense predictors to PP3/BP4 strength levels using ClinVar P/B variants with leave-one-gene-out cross-validation.

Predictor	BP4_Strong	BP4_Moderate	BP4_Supporting	PP3_Supporting	PP3_Moderate	PP3_Strong	Fails when
REVEL	<= 0.003	<= 0.016	<= 0.290	>= 0.644	>= 0.773	>= 0.932	Stacked with BayesDel/VEST4 (training overlap; double-counting)
BayesDel (no AF)	<= -0.36	<= -0.18	<= -0.08	>= 0.13	>= 0.27	>= 0.50	Combined with AF-aware variant (use no-AF version with PM2_Supporting)
VEST4	<= 0.302	<= 0.449	<= 0.302	>= 0.764	>= 0.861	>= 0.965	Indels (missense-trained); regulatory variants
MutPred2	(Pejaver 2022)	--	--	--	--	--	Genes with sparse MAVE training data
AlphaMissense	NOT ClinGen-endorsed	--	--	Use as supporting only	--	NOT ClinGen-endorsed	Developer threshold 0.564 misapplied as PP3

The two numbers to memorize: REVEL >= 0.932 = PP3_Strong; REVEL <= 0.290 = BP4_Strong (or <= 0.003 BP4_VeryStrong).

AlphaMissense calibration (Schmidt 2025 Genet Med 27:e101339, originally Pejaver et al. bioRxiv 2024.09.17): AlphaMissense reaches PP3_Strong and BP4_Moderate at calibrated thresholds. Critical: the developer-recommended 0.564 threshold is NOT the Pejaver PP3 threshold. ClinGen has NOT endorsed AlphaMissense PP3 strength as of May 2026; treat as supporting evidence only.

Do not stack predictors. REVEL, BayesDel, VEST4 share ClinVar/HGMD training data; using REVEL >= 0.773 AND BayesDel >= 0.27 to claim "two independent moderate hits" is double-counting. Pejaver 2022 explicitly recommends using ONE predictor per variant.

PM2_Supporting (ClinGen SVI 2020)

The original PM2 ("absent from controls") was over-weighted. SVI 2020 downgraded to PM2_Supporting (1 point, not 2). Mechanism: most rare variants are benign. Empirical recalibration showed ~6 variants per gene downgrade from LP to VUS when PM2 -> Supporting. Many 2017-2019 LP curations require re-classification post-SVI 2020 update.

PS3/BS3 Functional Evidence (Brnich 2020 Genome Med 12:3)

OddsPath framework; the four-step SOP:

1. Define disease mechanism for the gene.
2. Evaluate assay class (e.g., MAVE, biochemical, animal model).
3. Evaluate specific assay instance (controls, replicate consistency).
4. Apply per-variant.

OddsPath calibration mapping to ACMG strengths:

OddsPath	Pathogenic strength	Benign strength
> 18.7	Very Strong	n/a
4.3 - 18.7	Strong	--
2.1 - 4.3	Moderate	--
1.2 - 2.1	Supporting	(mirror)

MAVEdb deep-mutational scans with >=11 controls (>=5 P/LP + >=5 B/LB) can yield up to PS3_Strong/BS3_Strong via OddsPath calibration. This is the entry point for MAVE/saturation-mutagenesis evidence into ACMG.

Default-Strong PS3 application is increasingly over-strengthening without OddsPath calibration; ClinGen SVI recommends moving toward PS3_Moderate as default unless OddsPath > 4.3.

ClinGen SVI Splicing Subgroup 2023 (Walker AJHG 110:1046)

SpliceAI is the recommended primary splicing tool. Calibrated thresholds:

SpliceAI DS_max	Strength
>= 0.5 (Jaganathan 2019 default)	Can support PP3_Strong with corroborating evidence
>= 0.20	Minimum threshold for ANY splicing PP3
< 0.1	BP4_Moderate (weaker than missense BP4 because absence of predicted aberrant splicing is less informative)

SpliceVault / 300K-RNA (Dawes 2023 Nat Genet 55:324): does NOT predict whether a variant is splice-altering; predicts WHAT the aberrant transcript will be (which exon skips, which cryptic site activates). 96% sensitivity for exon-skipping; 86% for cryptic site activation in 140 clinical RNA-tested cases. Critical for PVS1 application to splice variants because PVS1 depends on whether the aberrant transcript triggers NMD.

Pangolin (Zeng 2022 Genome Biol 23:103): SpliceAI improvement for cryptic donor sites; not yet ClinGen-endorsed but increasingly used as tiebreaker.

BS1 / BA1 (Whiffin Max-Credible-AF)

BA1 default: AF > 5% in non-bottleneck group per ClinGen SVI; VCEP-specific overrides (Hearing Loss VCEP uses 0.5% AR).

BS1 gene-specific: (prevalence x heterogeneity x allelic-contribution) / (penetrance x 2) from Whiffin 2017 Genet Med 19:1151. Compare against gnomAD grpmax_faf95.

See clinical-databases/gnomad-frequencies for FAF95 details.

ClinGen VCEP CSpec Hierarchy

Layer	Authority	Application
Generic ACMG/AMP 2015	Richards 2015	Default fallback
ClinGen SVI specifications	SVI Working Group	Overrides generic for all genes (PM2 -> Supporting; AutoPVS1 trees; etc.)
VCEP-specific CSpec	Gene/disease-specific expert panel	Overrides SVI for that gene-disease

ClinGen VCEP CSpec authoritative registry: https://cspec.genome.network/cspec/ui/svi/all. ~80-90 VCEPs as of 2025. Examples:

• Hearing Loss VCEP: PM2 -> supporting default; PS3 thresholds upgraded for OTOF; BA1 lowered to 0.5% AR.
• ENIGMA BRCA1/2 VCEP: gene-specific PVS1 trees with NMD escape rules; PS4 case-control thresholds.
• Inherited Cardiac Conditions VCEP: gene-specific PS4 (5+ unrelated probands for PS4_Supporting).

Apply VCEP CSpec when one exists. Generic ACMG with no VCEP awareness is unreliable for many genes.

Cancer Somatic Framework (Li 2017 J Mol Diagn 19:4)

AMP/ASCO/CAP somatic variant interpretation; four tiers:

Tier	Definition	Action
Tier I-A	FDA-approved drug for same tumor type with this biomarker	On-label therapy
Tier I-B	Professional guidelines (NCCN, ESMO)	Standard-of-care
Tier II-C	FDA drug in different tumor type (off-label)	Basket trials
Tier II-D	Preclinical / investigational	Research
Tier III	VUS-somatic	Watch list
Tier IV	Benign-somatic	Filter out

Knowledgebases: OncoKB (MSKCC; Chakravarty 2017), CIViC (Griffith 2017 Nat Genet 49:170), CGI (Tamborero 2018), JAX-CKB, COSMIC. OncoKB Levels (1-4 therapeutic) map to AMP tiers loosely.

The Variant Interpretation for Cancer Consortium (VICC) Meta-Knowledgebase standards (2024-2025) harmonize across knowledgebases. ClinGen Somatic VCEPs are emerging (started 2022).

Decision Tree by Variant Type

Variant type	Recommended workflow
Predicted LoF in known LoF-mechanism gene	AutoPVS1 decision tree -> PVS1_VeryStrong/Strong/Moderate/Supporting; check VCEP-specific PVS1
Missense in known missense-pathogenic gene	Apply Pejaver 2022 PP3/BP4 calibrated thresholds; ONE predictor only
Splice variant	SpliceAI DS_max + SpliceVault for aberrant-transcript prediction; PP3_Strong if >=0.5 with corroborating evidence
Synonymous	SpliceAI for cryptic splice effect; synVep / PrimateAI synonymous extension
Variant in ACMG SF v3.2 gene	Apply full classification; flag P/LP for opt-in disclosure
Cancer somatic variant	AMP/ASCO/CAP 2017 Tier I-IV; cross-check OncoKB / CIViC
Variant in Limited gene-disease validity	ClinGen Strong/Definitive required for clinical action
Functional evidence available	Brnich 2020 PS3/BS3 OddsPath framework
Family segregation	PP1 / BS4 LOD score per Bayrak-Toydemir 2021
In-trans observations (AR)	PM3 with ClinGen tabular scoring system
HGVS-c on alternative transcript	Re-evaluate on MANE Select

Standard Workflow: ACMG Classification

Goal: Apply ACMG/AMP framework to a candidate variant with proper SVI specifications and VCEP overrides.

Approach: Pull aggregated evidence; apply Pejaver-calibrated in-silico thresholds; check VCEP-specific CSpec; sum Tavtigian points.

import requests
import pandas as pd


# Pejaver 2022 calibrated REVEL thresholds (one-predictor rule applies)
REVEL_THRESHOLDS = {
    'BP4_VeryStrong': (-float('inf'), 0.003),
    'BP4_Strong': (0.003, 0.016),
    'BP4_Moderate': (0.016, 0.290),
    'BP4_Supporting': (0.290, 0.644),
    'PP3_Supporting': (0.644, 0.773),
    'PP3_Moderate': (0.773, 0.932),
    'PP3_Strong': (0.932, float('inf'))
}

# Tavtigian point assignments (Tavtigian 2020 Hum Mutat)
STRENGTH_POINTS = {
    'PVS1_VeryStrong': 8, 'PVS1_Strong': 4, 'PVS1_Moderate': 2, 'PVS1_Supporting': 1,
    'PS1': 4, 'PS2': 4, 'PS3': 4, 'PS3_Moderate': 2, 'PS3_Supporting': 1, 'PS4': 4,
    'PM1': 2, 'PM2_Supporting': 1, 'PM3': , : , : ,
    : , : , : ,
    : , : , : ,
    : , : , : , : , : , : ,
    
    : -,  
    : -, : -, : -, : -, : -, : -,
    : -, : -, : -,
    : -, : -, : -, : -,
    : -, : -, : -
}


 ():
    
     revel_score  :
         
     code, (lo, hi)  REVEL_THRESHOLDS.items():
         lo <= revel_score < hi:
             code
     


 ():
    
     am_score  :
         
     am_score >= :
            
     am_score <= :
            
     


 ():
    
     ds_max  :
         
     ds_max >= :
           
     ds_max >= :
         
     ds_max < :
         
     


 ():
    
    points = (STRENGTH_POINTS.get(c, )  c  criteria_assigned)
     (c ==   c  criteria_assigned):
         {: , : points, : }
     points >= :
        category = 
     points >= :
        category = 
     points >= :
        category = 
     points >= -:
        category = 
    :
        category = 
     {: category, : points, : criteria_assigned}


 ():
    
    r = requests.get(,
                     params={: hgvs, : },
                     timeout=)
    r.raise_for_status()
     r.json()


 ():
    
     (prevalence * max_genetic_contribution * max_allelic_contribution) / (penetrance * )


 ():
    
     grpmax_faf95    grpmax_faf95 == :
         
     grpmax_faf95 > ba1_threshold:
         
     grpmax_faf95 > max_credible_af:
         
     

Per-Operation Failure Modes

1. Stacking REVEL + BayesDel + VEST4 as independent evidence

• Trigger: Apply PP3 from multiple predictors.
• Mechanism: Predictors share training data; double-counting.
• Symptom: Inflated PP3 strength; over-classified LP.
• Fix: Use ONE predictor per variant (Pejaver 2022).

2. AlphaMissense PP3_Strong with developer 0.564 threshold

• Trigger: Apply AlphaMissense >0.564 -> PP3_Strong.
• Mechanism: 0.564 is the developer-recommended likely-pathogenic threshold; NOT the Pejaver 2022 PP3-Strong calibration; ClinGen has not endorsed.
• Symptom: Over-application of PP3.
• Fix: Use AlphaMissense as supporting evidence only; defer to Pejaver-calibrated REVEL.

3. PVS1 applied to nonsense variant in GoF gene

• Trigger: Nonsense variant in SCN5A reported as PVS1 for LQT3.
• Mechanism: SCN5A has both LoF (Brugada) and GoF (LQT3) mechanisms. PVS1 should NOT apply if LoF is not the established mechanism.
• Symptom: Wrong classification; clinical action mis-directed.
• Fix: Check ClinGen gene-disease mechanism; apply PVS1 only when LoF is established.

4. Generic ACMG instead of VCEP CSpec

• Trigger: Apply default ACMG to a variant in a gene with VCEP-specific CSpec.
• Mechanism: VCEP CSpec overrides for the gene; e.g., Hearing Loss VCEP PM2 default = supporting, BA1 = 0.5%.
• Symptom: Wrong strength applied; misclassification.
• Fix: Check https://cspec.genome.network/cspec/ui/svi/all for active VCEP; apply gene-specific CSpec.

5. PM2 at Moderate (pre-2020 SVI)

• Trigger: Apply PM2 = Moderate (2 points) per 2015 rules.
• Mechanism: SVI 2020 downgraded to PM2_Supporting (1 point).
• Symptom: ~6 variants per gene over-strengthened LP.
• Fix: Use PM2_Supporting per current SVI.

6. PS3 default Strong without OddsPath

• Trigger: Apply PS3 = Strong without OddsPath calibration.
• Mechanism: Default PS3 = Strong over-strengthens; Brnich 2020 SOP requires OddsPath > 4.3 for Strong.
• Symptom: PS3-driven over-classification.
• Fix: Apply Brnich 2020 four-step OddsPath; default move to PS3_Moderate without OddsPath > 4.3.

7. Synonymous treated as no impact

• Trigger: Filter out synonymous variants from classification pipeline.
• Mechanism: Synonymous can disrupt splicing; SpliceAI captures this.
• Symptom: Pathogenic splice-disrupting synonymous missed.
• Fix: Always run SpliceAI on synonymous variants in disease genes; PP3_Strong if DS_max >= 0.5.

8. ClinVar P + ClinGen Limited validity

• Trigger: Report variant P in gene with Limited gene-disease validity.
• Mechanism: ClinVar P is variant-level; gene-disease validity is upstream.
• Symptom: Mis-attribution to a non-disease gene.
• Fix: Apply ClinGen gene-disease validity gate (Moderate+ for clinical action); for Limited genes, require VCEP curation.

9. Variant on wrong transcript

• Trigger: HGVS-c on alt transcript; functional impact different on MANE Select.
• Mechanism: Tissue-specific isoform considerations; MANE Select 2024+ is clinical standard.
• Symptom: Wrong consequence prediction.
• Fix: Re-evaluate on MANE Select transcript; cross-check with VEP --mane_select.

Reconciliation: When Tools Disagree

Pattern	Likely cause	Action
GeneBe LP vs VarSome P	Different VCEP-specific application	Check VCEP CSpec; apply gene-specific rules
ClinVar P vs my classification VUS	Submission stale OR my evidence incomplete	Re-curate with current evidence; check ClinVar star + freshness
REVEL PP3_Strong vs SpliceAI BP4	Variant has missense impact but no splice impact	Apply ONE predictor; if splice-altering, PVS1 trumps
PVS1 applies but ClinGen Limited validity	Variant-level vs gene-disease tension	Treat as candidate; require VCEP or strong functional evidence
ClinGen VCI vs automated tool	VCI is gold standard for expert curation	Trust VCI; automated tools approximate
AlphaMissense >0.564 + Pejaver PP3_Supporting only	Developer threshold not calibrated	Use Pejaver REVEL or BayesDel calibration

Quantitative Thresholds and Conventions

Threshold	Convention	Source
Tavtigian P	>= 10 points	Tavtigian 2020
Tavtigian LP	6-9 points	Tavtigian 2020
Tavtigian VUS	0-5 points	Tavtigian 2020
Tavtigian LB	-1 to -6	Tavtigian 2020
Tavtigian B	<= -7	Tavtigian 2020
REVEL PP3_Strong	>= 0.932	Pejaver 2022
REVEL BP4_Strong	<= 0.016	Pejaver 2022
SpliceAI PP3_Strong	>= 0.5 (with corroboration)	Walker 2023
SpliceAI minimum for PP3	>= 0.20	Walker 2023
SpliceAI BP4_Moderate	< 0.1	Walker 2023
BA1 default	grpmax_faf95 > 5%	ClinGen SVI
BS1	grpmax_faf95 > gene-specific max-credible-AF	Whiffin 2017
PM2 -> PM2_Supporting	Always (post-SVI 2020)	SVI 2020
PS3 OddsPath Strong	> 4.3	Brnich 2020
PVS1 LoF mechanism check	Required (do not apply if GoF)	Abou Tayoun 2018
ACMG SF v3.2	81 genes	Miller 2023
Cancer Tier I-A	FDA drug + same tumor + this biomarker	Li 2017

Common Errors

Symptom	Cause	Solution
Over-application of PP3	Multiple predictors stacked	ONE predictor only
AlphaMissense PP3_Strong from dev threshold	0.564 not calibrated	Use Pejaver-style REVEL
LP variant in gene with Limited validity	No gene-disease gate	Apply ClinGen gene-disease validity
PVS1 in GoF gene	Wrong mechanism	Check ClinGen gene-disease mechanism
Non-VCEP rule for VCEP-covered gene	Generic ACMG	Apply VCEP CSpec
PM2 = Moderate	Pre-SVI 2020	Use PM2_Supporting
PS3 = Strong default	No OddsPath	Apply Brnich 2020 OddsPath

Anticipated Reviewer Pushback

Pushback	Standard response
"Why Tavtigian point system?"	Every modern automated classifier implements it (InterVar, GeneBe, VarSome, Franklin). The 2015 combining rules are subsumed; many P/LP combinations only emerge from points.
"Why ONE predictor and not REVEL + BayesDel?"	Pejaver 2022 explicit recommendation; predictors share training data.
"AlphaMissense PP3_Strong?"	Treated as supporting only (Schmidt 2025 / Pejaver follow-up); ClinGen has not endorsed strength-graded thresholds.
"PVS1 for nonsense in SCN5A LQT3"	LQT3 is GoF; LoF mechanism not established; PVS1 does not apply.
"Generic ACMG vs VCEP"	VCEP CSpec overrides generic; we check cspec.genome.network for active VCEP.
"Splice variant PP3 from SpliceAI"	Walker 2023 SVI Splicing Subgroup: minimum DS_max >= 0.2 for ANY PP3; >= 0.5 + corroborating for PP3_Strong.
"PM2 Moderate or Supporting?"	SVI 2020 downgraded to Supporting; we use Supporting for all classification post-2020.

References

• Richards S et al. 2015. Standards and guidelines for the interpretation of sequence variants. Genet Med 17:405. (Original ACMG/AMP)
• Tavtigian SV et al. 2018. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med 20:1054.
• Tavtigian SV et al. 2020. Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat 41:1734.
• Abou Tayoun AN et al. 2018. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat 39:1517.
• Pejaver V et al. 2022. Calibration of computational tools for missense variant pathogenicity classification. Am J Hum Genet 109:2163.
• Schmidt H et al. 2025. Calibration of additional missense predictors including AlphaMissense. Genet Med 27:e101339.
• Brnich SE et al. 2020. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med 12:3.
• Walker LC et al. 2023. ClinGen SVI Splicing Subgroup recommendations. Am J Hum Genet 110:1046.
• Bayrak-Toydemir P et al. 2021. Disease-specific LOD score modifications for ACMG/AMP variant interpretation. Hum Mutat 42:1456. (PP1 segregation)
• Cheng J et al. 2023. Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 381:eadg7492.
• Jaganathan K et al. 2019. Predicting splicing from primary sequence with deep learning. Cell 176:535. (SpliceAI)
• Zeng T et al. 2022. Predicting RNA splicing from DNA sequence using Pangolin. Genome Biol 23:103.
• Dawes R et al. 2023. SpliceVault predicts the precise nature of variant-associated mis-splicing. Nat Genet 55:324.
• Whiffin N et al. 2017. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med 19:1151.
• Li MM et al. 2017. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn 19:4. (AMP/ASCO/CAP)
• Miller DT et al. 2023. ACMG SF v3.2 list. Genet Med 25:100866.
• Stawinski PM et al. 2024. GeneBe; automated ACMG/AMP variant interpretation. Clin Genet (verify exact volume/pages in the published record before citing).
• Kopanos C et al. 2019. VarSome: the human genomic variant search engine. Bioinformatics 35:1978.
• Li Q, Wang K. 2017. InterVar: clinical interpretation of genetic variants. Am J Hum Genet 100:267.
• Xiang J et al. 2020. AutoPVS1 -- automated PVS1 decision-tree implementation (verify exact venue/year against the published code/release).

Related Skills

• clinical-databases/variant-prioritization - Rare-disease pipeline (filters variants; this skill classifies)
• clinical-databases/clinvar-lookup - ClinVar evidence aggregation
• clinical-databases/gnomad-frequencies - BS1/BA1 with Whiffin FAF95
• clinical-databases/myvariant-queries - Aggregated annotation pull
• variant-calling/clinical-interpretation - Clinical reporting workflow